
Prolintane Metabolites. Synthesis of dl-1-(α -Propylphenethyl)pyrrolidin-2-one

David C. Remy,* William A. Van Saun, Jr., and Victor J. Lotti

Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486. Received March 6, 1972

Although prolintane,¹ 1-(α -propylphenethyl)pyrrolidine, has been used as a stimulant drug for over a decade, little is known concerning its metabolism in animal or man. Eberhardt and Debackere² demonstrated the presence of possible prolintane metabolites in human urine, but no characterization of these urinary substances was undertaken. The present work was carried out in connection with a study of the metabolism and pharmacology of prolintane. The lactam 6 has been shown to be the single major metabolite of prolintane in a rabbit liver microsomal system, as well as a metabolite in tissues of rats given the drug.³ Compared to prolintane (ED₅₀ 1.8 mg/kg po), the lactam 6 and the amino acid 5 (ED₅₀'s > 32.0 mg/kg po) showed little ability to antagonize the sedative action of tetrabenazine in mice as determined by the method of Vernier, *et al.*⁴



Experimental Section

Where analyses are indicated only by symbols of the elements or functions, analytical results obtained for those elements or functions were within $\pm 0.4\%$ of the theoretical values. Tlc was performed on fluorescent silica gel G plates. All bp are uncorrected; mp were taken on a Thomas-Hoover Uni-Melt capillary mp apparatus and are uncorrected.

Benzyl *n*-propyl ketone (1) was prepared by the method of Bredereck and Gompper: bp 113-117° (12 mm); n^{25} D 1.5051; 43% [lit.⁵ bp 115-117° (11 mm); 45%]. *dl*- α -Propylphenethylamine (2) was prepared from benzyl *n*-propyl ketoxime by reduction with sodium in refluxing ethanol.⁶ The oil obtained after work-up was distilled giving 8.71 g (80.5%) of 2: bp 112-118° (14-15 mm) [lit.⁷ bp 118° (15 mm); 67%]. 4-Iodobutyronitrile was prepared by the method of Leonard and Goode: bp 115-116° (16 mm); n^{25} D 1.5369; 68% [lit.⁸ bp 109-111° (15 mm), 92%; lit.⁹ n^{21} D 1.5358].

di-1-(α -Propylphenethyl)-2-iminopyrrolidine (4). A homogeneous soln of 5.20 g (0.0267 mole) of 4-iodobutyronitrile and 8.71 g (0.0534 mole) of 2 in 35 ml of C₆H₆ was stirred and refluxed for 21 hr. The resulting two-phase mixt was sepd and the lower oily phase was dissolved in 1.5 N HCl (200 ml). After washing with C₆H₆, the aqueous phase was made basic with 40% NaOH. The oil that pptd was extd into C₆H₆, dried (MgSO₄), and distd to give 3.70 g (60%) of 4 as a viscous, clear fuming oil: bp 135-136° (1 mm); ir (liq film) 3290 cm⁻¹ (NH), 1616 (C=N). The compd had a strong odor resembling pyrrolidine and appeared to absorb CO₂ and H₂O rapidly. No consistent analytical data could be obtained on the compd, and it was used for the next step without further characterization.

dl-(α -Benzyl-*n*-butyl)-4-aminobutyric Acid (5). Into a stainless steel flask was placed 3.00 g (0.013 mole) of 4, 15.0 g of Ba(OH)₂. 8H₂O, 15 ml of water, and 8 ml of *n*-PrOH. The mixt was stirred and refluxed for 36 hr. Initially, there was a copious evolution of NH₃. The mixt was evapd to dryness *in vacuo*. The residue was extd several times with Me₂CO, and the combined exts were filtered. Concn of the filtrate gave 2.96 g of a clear oil. This oil was

dissolved in aqueous EtOH (1:1), and CO₂ gas was bubbled into the soln until it reached pH 7. The pptd BaCO₃ was removed by filtration, and the clear filtrate was concd. The residue, on trituration with Me₂CO, crystd as white needles. Recrystn from Me₂CO-EtOH gave 0.79 g (25%) of 5: mp 137-137.5°; $pK_a = 4.00$, $pK_B =$ 9.72; equiv wt 253.1 (titrn); $R_f 0.60$ (*n*-BuOH-AcOH-H₂O, 3:1:1), $R_f 0.04$ (C₆H₆-dioxane-AcOH, 90:25:4) ninhydrin-developed spots. Anal. (C₁₅H₂₃NO₂) C, H, N.

dl-1-(α -Propylphenethyl)pyrrolidin-2-one (6) was prepd by heating the amino acid 5 at 70° under reduced pressure or by melting 5. The product was purified by distn: bp 125-126° (0.05 mm); n^{20} D 1.5256; R_f 0.60 (C_gH_6 -EtOH-12 N NH₄OH, 95:15:5). Anal. ($C_{15}H_{21}$ NO·0.05H₂O) C, H, N, H₂O.

Acknowledgment. The authors wish to thank K. B. Streeter, Y. C. Lee, and their staff for elemental analyses, and W. R. McGaughran for the infrared spectra and water analysis.

References


- (1) R. Kadatz and E. Potzsch, Arzneim. Forsch., 7, 344 (1957).
- (2) H. Eberhardt and M. Debackere, *ibid.*, **15**, 929 (1965).
- (3) H. B. Hucker, S. C. Stauffer, and R. E. Rhodes, *Experientia*, 28, 430 (1972).
- (4) V. G. Vernier, H. M. Hanson, and C. A. Stone, "First Hahnemann Symposium on Psychosomatic Medicine," J. H. Nodine and J. H. Moyer, Ed., Lea and Febiger, Philadelphia, Pa., 1962, p 683.
- (5) H. Bredereck and R. Gompper, Ber., 87, 700 (1954).
- (6) S. Ishiwata and K. Suzuki, Yakugaku Zasshi, 71, 1263 (1951); Chem. Abstr., 46, 5590 (1952).
- (7) N. Kornblum and D. C. Iffland, J. Amer. Chem. Soc., 71, 2137 (1949).
- (8) N. J. Leonard and W. E. Goode, *ibid.*, 72, 5404 (1950).
- (9) R. H. Martin, J. Pecher, J. Puters, and C. vonMalder, Bull. Soc. Chim. Belges, 67, 256 (1958); Chem. Abstr., 53, 12300 (1959).

Hydroxylamine Derivatives as Potential Antimalarial Agents. 3. 1,2,4-Oxadiazoles[†],[‡]

John B. Hynes* and Roy F. Gratz

Department of Pharmaceutical Chemistry, College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina 29401. Received May 15, 1972

In 1970, it was reported that, in addition to displaying a broad spectrum of anthelmintic activity, $\alpha, \alpha, \alpha, \alpha', \alpha', \alpha'$ hexachloro-*p*-xylene, Hetol (1), also possessed substantial suppressive antimalarial properties.² Subsequently, certain 2-(trichloromethyl)-5-(trichloromethylphenyl)-1,3,4-oxadiazoles such as 2 were shown to have similar levels of activity as 1 against *Plasmodium berghei* in mice.³ Therefore, a



series of mono-, bis-, and tris(trihalomethylated-1,2,4-oxadiazoyl)benzenes was synthesized and evaluated for possible activity enhancement. These compounds were prepared by the reaction of an amidoxime with the appropriate acid chloride or anhydride. The physical properties of the bis-(1,2,4-oxadiazoles) are presented in Table I while those of the mono- and tris(1,2,4-oxadiazoles) as well as certain intermediate amidoximes are summarized in Table II.

[†]This work was supported by U. S. Army Medical Research and Development Command Contract No. DADA 17-69-C-9066 and is Contribution No. 1076 to the Army Research Program on Malaria.

[‡]For the previous paper in this series see ref 1.